Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | BCR | P11274 | 8/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543764 | 0.90 | ABL1 (0.55) | ABL1MEN1MAPTKMT2ALMNA | |
| SCHEMBL543704 | 0.88 | ABL1 (0.56) | ABL1MEN1MAPTKMT2ALMNA | |
| SCHEMBL543557 | 0.86 | ABL1 (0.57) | ABL1MEN1MAPTKMT2ALMNA | |
| SCHEMBL544438 | 0.86 | BRAF (0.53) | ABL1MEN1MAPTKMT2ALMNA | |
| SCHEMBL543697 | 0.85 | ABL1 (0.64) | ABL1MEN1MAPTKMT2ALMNA | |
| SCHEMBL14400775 | 0.84 | ABL1 (0.52) | ABL1MEN1MAPTKMT2ALMNA | |
| SCHEMBL544551 | 0.84 | ABL1 (0.52) | ABL1MEN1MAPTKMT2ALMNA | |
| SCHEMBL544504 | 0.81 | ABL1 (0.58) | ABL1BCRPDGFRBHDAC3KDR | |
| SCHEMBL543648 | 0.81 | PORCN (0.49) | ABL1BCRPDGFRBKDRPDGFRA | |
| SCHEMBL544211 | 0.79 | ABL1 (0.58) | ABL1BCRPDGFRBHDAC3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | claimed |
| EP-1684750-B1 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2010-04-28 | — | — | EP | claimed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | claimed |
| EP-1684750-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB Science (FR) | 2006-08-02 | — | — | EP | claimed |
| WO-2005040139-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2005-05-06 | — | — | WO | claimed |
| US-8110591-B2 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-02-07 | — | — | US | disclosed |
| US-8110591-B2 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-02-07 | — | — | US | disclosed |
| US-8110591-B2 | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-02-07 | — | — | US | disclosed |
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | disclosed |
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | disclosed |
| US-7718676-B2 | E.g., Methyl 4-{[4-Methyl-3-(4-pyridin-3-yl-oxazol-2-ylamino)-phenylamino]-methyl}-benzoate; stem cell factor, bcr-abl, fibroblastic growth factor receptor-3 and Flt-3 inhibitors; treating rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, transplant rejection | AB SCIENCE (FR) | 2010-05-18 | — | — | US | disclosed |
| US-20100113471-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2010-05-06 | — | — | US | disclosed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | disclosed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | disclosed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | disclosed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | disclosed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | disclosed |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | AB SCIENCE | 2007-06-21 | — | — | US | disclosed |
| EP-1684750-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB Science (FR) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005040139-A2 | 2-AMINOARYLOXAZOLE COMPOUNDS AS TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | KIT, CPA3, CMA1 | ABL1 419/4885MEN1 2998/4885MAPT 4472/4885 |
| US-20070142390-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | FGFR3, ABL1, FLT3 | ABL1 2/4885MEN1 4358/4885MAPT 2618/4885 |
| US-20100113471-A1 | 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors | FGFR3, FLT3, ABL1 | ABL1 3/4885MEN1 4471/4885MAPT 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.